These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18497829)

  • 21. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.
    Bressler SB
    Ophthalmology; 2009 Oct; 116(10 Suppl):S1-7. PubMed ID: 19800534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
    Nguyen TT; Guymer R
    Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies.
    Csaky K; Do DV
    Am J Ophthalmol; 2009 Nov; 148(5):647-56. PubMed ID: 19712924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegaptanib for wet macular degeneration.
    Fraunfelder FW
    Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preferred therapies for neovascular age-related macular degeneration.
    Chiang A; Regillo CD
    Curr Opin Ophthalmol; 2011 May; 22(3):199-204. PubMed ID: 21427571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
    Andreoli CM; Miller JW
    Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.
    Kaiser PK
    Am J Ophthalmol; 2006 Oct; 142(4):660-8. PubMed ID: 17011860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
    Lu F; Adelman RA
    Graefes Arch Clin Exp Ophthalmol; 2009 Feb; 247(2):171-7. PubMed ID: 18781316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis.
    Fine HF; Zhitomirsky I; Freund KB; Barile GR; Shirkey BL; Samson CM; Yannuzzi LA
    Retina; 2009 Jan; 29(1):8-12. PubMed ID: 18784620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M; Sharma S
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiangiogenic therapy in neovascular age-related macular degeneration.
    Lin RC; Rosenfeld PJ
    Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
    Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
    Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration.
    Dadgostar H; Waheed N
    Eye (Lond); 2008 Jun; 22(6):761-7. PubMed ID: 18388961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Abrams P
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
    Spandau UH; Jonas JB
    Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-VEGF therapy: riding the wave of change.
    Hunyor AP
    Clin Exp Ophthalmol; 2008 Jul; 36(5):401-2. PubMed ID: 18925912
    [No Abstract]   [Full Text] [Related]  

  • 38. [Introduction to the topic: anti-VEGF therapy in the management of AMD].
    Meyer CH
    Ophthalmologe; 2008 Feb; 105(2):123-4. PubMed ID: 18256843
    [No Abstract]   [Full Text] [Related]  

  • 39. [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].
    Klin Monbl Augenheilkd; 2007 Jul; 224(7):559-66. PubMed ID: 17657689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.